Looking past COPD, Regeneron CSO George Yancopoulos says Dupixent's 'next big thing' is reversing allergies
SAN FRANCISCO — While Dupixent could add a major new indication in COPD this year, Regeneron’s longtime top scientist is already excited by the next bold idea for its immunology blockbuster.
George Yancopoulos, Regeneron’s chief scientific officer, said Dupixent’s potential to reverse severe allergies is the “next big thing” for the biologic that is co-developed by Regeneron and Sanofi. The $102 billion biotech giant expects to start a small proof-of-concept study in humans this year in volunteers with severe food allergies, giving a single dose of an experimental cancer drug followed by regular injections of Dupixent.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
